U.S.-China Trade Breakthrough Sparks Market Rally Amid Pharma Sector Shakeup.

After weeks of tense negotiations, the U.S. and China have reached preliminary agreements addressing several key trade imbalances. China has committed to significantly increasing its imports of U.S. agricultural products and advanced technology, a move aimed at easing tariff tensions and stabilizing market relations. This morning, markets responded swiftly, with tech and manufacturing stocks leading the rally, while some sectors exposed to prior tariffs saw sharp recoveries. Are you repositioning your portfolio to align with these new trade dynamics, or maintaining a more conservative stance and how as the pharma market is being shaken up. An expected executive order implements price caps on select high-cost prescription drugs, sending shockwaves through the pharmaceutical sector. As some drugmakers adjust their revenue projections downward, are you considering reallocating assets within the healthcare sector to mitigate potential earnings hits? Following the U.S.-China trade announcement, the S\&P 500 surged 1.2%, led by tech and industrials, while the NASDAQ gained 0.8%, reflecting renewed investor confidence in sectors poised to benefit from increased U.S. exports. Are you seizing these market movements, or holding steady for a broader market readjustment?